PortfoliosLab logoPortfoliosLab logo
EDIT vs. ECL
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

EDIT vs. ECL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Editas Medicine, Inc. (EDIT) and Ecolab Inc. (ECL). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, EDIT achieves a 21.95% return, which is significantly higher than ECL's 1.37% return. Over the past 10 years, EDIT has underperformed ECL with an annualized return of -22.22%, while ECL has yielded a comparatively higher 9.50% annualized return.


EDIT

1D
2.46%
1M
-4.58%
YTD
21.95%
6M
-1.19%
1Y
26.90%
3Y*
-39.82%
5Y*
-41.79%
10Y*
-22.22%

ECL

1D
0.68%
1M
7.18%
YTD
1.37%
6M
1.24%
1Y
1.50%
3Y*
14.71%
5Y*
5.51%
10Y*
9.50%
*Multi-year figures are annualized to reflect compound growth (CAGR)

EDIT vs. ECL - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
EDIT
Editas Medicine, Inc.
21.95%61.42%-87.46%14.21%-66.59%-62.13%136.78%30.15%-25.97%89.34%
ECL
Ecolab Inc.
1.37%13.19%19.29%37.94%-37.10%9.38%13.17%32.26%11.07%15.80%

Correlation

The correlation between EDIT and ECL is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.21

Correlation (3Y)
Calculated over the trailing 3-year period

0.21

Correlation (5Y)
Calculated over the trailing 5-year period

0.27

Correlation (10Y)
Calculated over the trailing 10-year period

0.25

Correlation (All Time)
Calculated using the full available price history since Feb 3, 2016

0.24

Fundamentals

Market Cap

EDIT:

$244.70M

ECL:

$75.30B

EPS

EDIT:

-$1.21

ECL:

$7.40

PS Ratio

EDIT:

6.29

ECL:

4.59

PB Ratio

EDIT:

55.51

ECL:

7.53

Total Revenue (TTM)

EDIT:

$35.86M

ECL:

$16.45B

Gross Profit (TTM)

EDIT:

$35.86M

ECL:

$7.29B

EBITDA (TTM)

EDIT:

-$76.66M

ECL:

$3.28B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

EDIT vs. ECL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EDIT
EDIT Risk / Return Rank: 5151
Overall Rank
EDIT Sharpe Ratio Rank: 4848
Sharpe Ratio Rank
EDIT Sortino Ratio Rank: 5656
Sortino Ratio Rank
EDIT Omega Ratio Rank: 5353
Omega Ratio Rank
EDIT Calmar Ratio Rank: 4949
Calmar Ratio Rank
EDIT Martin Ratio Rank: 4848
Martin Ratio Rank

ECL
ECL Risk / Return Rank: 3838
Overall Rank
ECL Sharpe Ratio Rank: 4141
Sharpe Ratio Rank
ECL Sortino Ratio Rank: 3434
Sortino Ratio Rank
ECL Omega Ratio Rank: 3434
Omega Ratio Rank
ECL Calmar Ratio Rank: 4141
Calmar Ratio Rank
ECL Martin Ratio Rank: 4040
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

EDIT vs. ECL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Editas Medicine, Inc. (EDIT) and Ecolab Inc. (ECL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


EDITECLDifference
Sharpe ratioReturn per unit of total volatility

+0.21

Sortino ratioReturn per unit of downside risk

+0.91

Omega ratioGain probability vs. loss probability

1.11

1.01

+0.10

Calmar ratioReturn relative to maximum drawdown

0.25

-0.05

+0.30

Martin ratioReturn relative to average drawdown

0.43

-0.12

+0.55

EDIT vs. ECL - Sharpe Ratio Comparison

The current EDIT Sharpe Ratio is 0.16, which is higher than the ECL Sharpe Ratio of -0.05. The chart below compares the historical Sharpe Ratios of EDIT and ECL, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

EDIT vs. ECL - Drawdown Comparison

The maximum EDIT drawdown since its inception was -98.92%, which is greater than ECL's maximum drawdown of -47.19%. Use the drawdown chart below to compare losses from any high point for EDIT and ECL.


Loading charts...

Drawdown Indicators


EDITECLDifference

Max Drawdown

Largest peak-to-trough decline

-98.92%

-47.19%

-51.73%

Max Drawdown (1Y)

Largest decline over 1 year

-59.88%

-20.09%

-39.79%

Max Drawdown (3Y)

Largest decline over 3 years

-91.18%

-20.09%

-71.09%

Max Drawdown (5Y)

Largest decline over 5 years

-98.66%

-43.70%

-54.96%

Max Drawdown (10Y)

Largest decline over 10 years

-98.92%

-43.70%

-55.22%

Current Drawdown

Current decline from peak

-97.24%

-13.70%

-83.54%

Average Drawdown

Average peak-to-trough decline

-62.63%

-7.98%

-54.65%

Ulcer Index

Depth and duration of drawdowns from previous peaks

34.03%

8.77%

+25.26%

Volatility

EDIT vs. ECL - Volatility Comparison

Editas Medicine, Inc. (EDIT) has a higher volatility of 32.34% compared to Ecolab Inc. (ECL) at 7.47%. This indicates that EDIT's price experiences larger fluctuations and is considered to be riskier than ECL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


EDITECLDifference

Volatility (1M)

Calculated over the trailing 1-month period

32.34%

7.47%

+24.87%

Volatility (6M)

Calculated over the trailing 6-month period

61.63%

15.88%

+45.75%

Volatility (1Y)

Calculated over the trailing 1-year period

94.75%

21.01%

+73.74%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

94.12%

23.89%

+70.23%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

83.80%

25.02%

+58.78%

Dividends

EDIT vs. ECL - Dividend Comparison

EDIT has not paid dividends to shareholders, while ECL's dividend yield for the trailing twelve months is around 1.04%.


PositionTTM20252024202320222021202020192018201720162015
ECL
Ecolab Inc.
1.04%1.02%1.01%1.09%1.42%0.83%0.87%0.96%1.15%1.13%1.21%1.17%
EDIT
Editas Medicine, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

EDIT vs. ECL - Financials Comparison

This section allows you to compare key financial metrics between Editas Medicine, Inc. and Ecolab Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.001.00B2.00B3.00B4.00B202220232024202520260
4.07B
(EDIT) Total Revenue
(ECL) Total Revenue
Values in USD except per share items

Frequently Asked Questions


EDIT and ECL have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

EDIT has higher volatility (32.34%) compared to ECL (7.47%). In terms of maximum drawdown, EDIT dropped -98.92% vs ECL's -47.19%.

EDIT currently has the higher Sharpe Ratio (0.16 vs -0.05), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for EDIT and ECL

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer